Andrea Lora (Lora) Kossler MD FACS
Oculo-Plastic & Orbital Reconstructive Surgery
Associate Professor of Ophthalmology Director, Oculofacial Plastic & Reconstructive Surgery Co-Director, Multidisciplinary Thyroid Eye Disease Center Co-Director, Orbital and Ocular Oncology Center
Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Dr. Kossler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Andrea Lora Kossler, MD, is Associate Professor of Ophthalmology at Stanford University School of Medicine and Director of the Ophthalmic Plastic, Reconstructive Surgery and Orbital Oncology Service. She specializes orbital reconstructive and aesthetic facial plastic surgery. Dr. Kossler’s research interests include thyroid eye disease and orbital oncology.
Education & Training
University of Miami Hospital and ClinicsFellowship, Ophthalmic Plastic and Reconstructive Surgery, 2010 - 2012
University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 2007 - 2010
Mount Sinai Medical Center of FloridaInternship, Internal Medicine, 2006 - 2007
Georgetown University School of MedicineClass of 2006
Certifications & Licensure
CA State Medical License 2012 - 2027
FL State Medical License 2010 - 2014
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- Annual AAO Conference: Best Ocular & Orbital Oncology Paper AAO- American Academy of Ophthalmology
Clinical Trials
- TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study Start of enrollment: 2021 Sep 16
- A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) Start of enrollment: 2021 Dec 03
- A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Start of enrollment: 2022 Jul 01
Publications & Presentations
PubMed
- Primary hypertrophic osteoarthropathy presenting with ptosis and floppy eyelids: a review of ophthalmic manifestations, histopathology, and pathophysiology.Maja Magazin, Aneesha Ahluwalia, Chaow Charoenkijkajorn, Andrea L Kossler
Orbit. 2026-06-01 - Teprotumumab associated menstrual changes.Amina Malik, Patrick J Hunt, Tracy Lu, Andrea Kossler, Karina Richani
Orbit. 2026-06-01 - THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease.Michael T Yen, Kimberly Cockerham, Peerooz Saeed, Steven Leibowitz, Raghu C Mudumbai
Ophthalmology. 2026-06-01
Journal Articles
- Bilateral Atypical Eyelid Lesions in a 50-Year-Old WomanEmily S Charlson, Andrea L Kossler, JAMA Ophthalmology
Authored Content
- Vibrating Device Relieves Pain at Anesthesia Injection SitesJanuary 2020
Press Mentions
New Drug Gives Patient His Sight BackMarch 23rd, 2022- The Impact on Ocular Surface Disease of Teprotumumab for TEDNovember 23rd, 2021
Professional Memberships
- Fellow
- Member
Other Languages
- Spanish
Industry Relationships
- Consultant, Immunovant Inc
- Consultant, Horizon Therapeutics
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
